Nucleome Therapeutics raises oversubscribed £37.5 million Series A

Nucleome Therapeutics Limited, a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

Nucleome has the unique ability to discover and validate first-in-class targets through genetics, by investigating the ‘dark’ region of the human genome, which does not encode for proteins but contains 90% of disease-associated genetic changes. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights.

Nucleome’s breakthrough platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery.

“We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets,” said Dr Danuta Jeziorska, Chief Executive Officer and Co-founder of Nucleome Therapeutics.  “

Click here to find out more.

Recent news

Greater Oxford: A Proposal for Local Government Reform

Greater Oxford: A Proposal for Local Government Reform

The government has asked councils across England for proposals on simplifying the structure of local government in their regions-  in March, Oxford City Council put forward outline proposals that would see Oxfordshire’s six councils abolished and replaced with three...

read more
New Report Reveals Economic Power of Health Innovation

New Report Reveals Economic Power of Health Innovation

Reducing ill-health and making better use of health innovations could add billions to economic growth in the UK, a new report reveals today.   ‘Defining the Size of the Health Innovation Prize’ was commissioned by Advanced Oxford member Health Innovation Oxford...

read more
British Land joins Advanced Oxford

British Land joins Advanced Oxford

Advanced Oxford is delighted to welcome British Land as a new member of the science and technology focused business leadership organisation. British Land will be contributing to our work in supporting the development of Oxfordshire’s innovation ecosystem. British Land...

read more
Loading...